- Levine EG, Bloomfield CD . Secondary myelodysplastic syndromes and leukaemias. Clin Haematol 1986; 15: 1037–1080.
CAS PubMed Google Scholar
- Borthakur G, Estey AE . Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007; 9: 373–377.
Article CAS PubMed Google Scholar
- Kushner BH, Kramer K, Modak S, Qin LX, Yataghena K, Jhanwar SC et al. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009; 53: 17–22.
Article PubMed Central PubMed Google Scholar
- Howe R, Micallef IN, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 32: 317–324.
Article CAS PubMed Google Scholar
- Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 655–664.
Article CAS PubMed Central PubMed Google Scholar
- Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850–1857.
Article CAS PubMed Central PubMed Google Scholar
- Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009; 94: 542–549.
Article PubMed Central PubMed Google Scholar
- Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.
CAS PubMed Google Scholar
- Bertz H, Spyridonidis A, Wäsch R, Grüllich C, Egger M, Finke J . A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009; 15: 1563–1570.
Article CAS PubMed Google Scholar
- Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.
Article CAS PubMed Google Scholar
- Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.
Article CAS PubMed Google Scholar
- Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Article CAS PubMed Google Scholar
- Yakoub-Agha I, de La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963–971.
Article CAS PubMed Google Scholar
- Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR . Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001; 19: 2134–2141.
Article CAS PubMed Google Scholar
- Armand P, Kim HT, Mayer E, Cutler CS, Ho VT, Koreth J et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 2010; 45: 1611–1617.
Article CAS PubMed Central PubMed Google Scholar
- Bhatia S . Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013; 40: 666–675.
Article CAS PubMed Google Scholar
- Steinmann J, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L et al. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant 2015; 50: 690–695.
Article CAS PubMed Google Scholar
- de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420–5431.
Article CAS PubMed Google Scholar
- Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.
Article CAS PubMed Google Scholar
- Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E et al. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Curr Cancer Drug Targets 2013; 13: 30–47.
Article CAS PubMed Google Scholar
- Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K . Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 2015; 6: 36.
Article PubMed Central PubMed Google Scholar
- Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A et al. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Int J Cancer 2015; 137: 2083–2092.
Article CAS PubMed Google Scholar
- Steger B, Milosevic S, Doessinger G, Reuther S, Liepert A, Braeu M et al. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. Immunobiology 2014; 219: 247–260.
Article CAS PubMed Google Scholar
- Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012; 30: 2140–2146.
Article PubMed Google Scholar
- Lübbert M, Bertz H, Müller MJ, Finke J . When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. J Clin Oncol 2013; 31: 822–823.
Article PubMed Google Scholar
- Ustun C, Lazarus HM, Weisdorf D . To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant 2013; 48: 1497–1505.
Article CAS PubMed Google Scholar
- Guo RJ, Atenafu EG, Craddock K, Chang H . Allogeneic hematopoietic cell transplantation may alleviate the negative prognostic impact of monosomal and complex karyotypes on patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: 690–695.
Article PubMed Google Scholar
- Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell 2011; 20: 591–605.
Article CAS PubMed Central PubMed Google Scholar
- Servais S, Porcher R, Xhaard A, Robin M, Masson E, Larghero J et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. Haematologica 2014; 99: 519–526.
Article PubMed Central PubMed Google Scholar
- Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.
Article PubMed Google Scholar